Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

July 19, 2024

Study Completion Date

July 19, 2024

Conditions
Major Depressive Disorder
Interventions
DRUG

Ropanicant

Tablet

Trial Locations (10)

30030

CenExel iResearch, LLC, Decatur

31405

CenExel iResearch, LLC, Savannah

33016

Innovative Clinical Research, Inc., Miami Lakes

39232

Precise Research Centers, Flowood

44720

Neuro behavioral Clinical Research, Inc, North Canton

84107

Cedar Clinical Research, Inc., Murray

90504

Collaborative Neuroscience Research, LLC, Torrance

90706

Clinical Innovations, Inc, Bellflower

92868

NRC Research Institute, Orange

98201

Eastside Therapeutic Resource, Inc. dba Core Clinical Research, Everett

All Listed Sponsors
lead

Suven Life Sciences Limited

INDUSTRY

NCT06126497 - Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients | Biotech Hunter | Biotech Hunter